Role of pelvic and para-aortic lymphadenectomy in abandoned radical hysterectomy in cervical cancer

Table 2 Comparison of patients group with pelvic lymph node surgery

	Tumor removal and/or pelvic biopsy N = 19 (57.6%)	Pelvic lymphadenectomy N = 14 (42.4%)	p
Country^a
Mexico (INCan)	10 (52.6)	2 (14.3)	0.02
Colombia (ICLA)	9 (47.4)	12 (85.7)	0.02
Age (years)^b	45 (35-53)	45.5 (40-54.3)	0.55
BMI ^b	27.4 (25.3–31.1)	24.6 (22.4–25.4)	0.01
Histology^a
Squamous	9 (47.4)	9 (64.3)	0.22
Adenocarcinoma	5 (26.3)	5 (35.7)
Adenosquamous	3 (15.8)	0
Others	2 (10.5)	0
Initial clinical stage^a
IB1	18 (94.7)	13 (92.9)	0.82
IB2	1 (5.3)	1 (7.1)	0.82
Tumor size (cm)^b	3 (1.6–4)	3 (2–4)	0.63
Tumor grade^a
Well-differentiated	4 (21.1)	7 (50)	0.05
Moderately differentiated	7 (36.8)	6 (42.9)
Poorly differentiated	8 (42.1)	1 (7.1)
LVSI^a	3 (15.8)	2 (14.3)	0.74
Systematic PAL^a	1 (5.3)	5 (35.7)	0.062
BPR^a	11 (57.9)	3 (21.4)	0.073
PR positive	17 (89.5)	12 (85.7)	NS
Surgical time (min)^b	150 (120–190)	165 (103.8–198.8)	0.69
Blood loss (mm)^b	100 (70–250)	100 (57.5–212.5)	0.78
Blood transfusion^a	1 (0.05)	1 (0.07)	0.82
Others complications^a	1 (0.05)	1 (0.07)	0.82
Hospital stay (days)^b	2 (2–2)	2 (2–3.3)	0.19
Neoadjuvant treatment term (weeks)^b	10 (7.5–14)	8.8 (8.1–11)	0.57
Recurrence^a	7 (26.8)	2 (14.3)	0.15
Local	1 (14.3)	0
Regional	6 (85.7)	2 (100)
Distance	0	0

Confidence interval 95%
BMI body mass index, Mod moderate, LVSI lymphovascular space involvement, PAL para-aortic lymphadenectomy, BPR biopsy or pelvic lymph node removal, PR pathology report, NS not significant
^a N (relative frequency)
^bMedian (interquartile range)

ISSN: 1477-7819